公开(公告)号：US11634398B2

公开(公告)日：2023-04-25

申请号：US16576178

申请日：2019-09-19

申请人： Celex Oncology Ltd.

发明人： Mustafa Djamgoz

IPC分类号： C07D295/15 ,  A61K31/00 ,  A61K31/428 ,  A61K31/495 ,  A61K31/138 ,  A61K31/167 ,  A61K31/19 ,  A61K31/4458 ,  C07D241/04 ,  C07D277/82

摘要： Substances and methods are dislosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

公开(公告)号：US20230121086A1

公开(公告)日：2023-04-20

申请号：US17790908

申请日：2020-12-31

申请人： SUNSHINE LAKE PHARMA CO., LTD.

发明人： Bing LIU ,  Yingjun ZHANG ,  Wei PAN ,  Feng WANG ,  Xuke LI ,  Wei HE ,  Jiuzhong HUANG

IPC分类号： A61K31/402 ,  A61K45/06 ,  A61P17/06 ,  A61P37/06 ,  C07D403/12 ,  C07D207/12 ,  C07D401/12 ,  C07D401/14 ,  C07D417/12 ,  C07D403/04 ,  C07D405/12 ,  C07D207/09 ,  C07D211/60 ,  C07D401/04 ,  C07D211/42 ,  C07D211/34 ,  C07D211/22 ,  C07D241/04 ,  C07D295/155 ,  C07D205/04 ,  C07D277/34 ,  C07D231/56 ,  C07D215/06 ,  C07D217/04 ,  C07C317/50 ,  C07D305/08 ,  C07F7/08 ,  A61K31/501 ,  A61K31/506 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/444 ,  A61K31/495 ,  A61K31/397 ,  A61K31/426 ,  A61K31/416 ,  A61K31/47 ,  A61K31/472 ,  A61K31/277 ,  A61K31/337 ,  A61K31/695

摘要： A RORγt inhibitor as well as a preparation method thereof and uses thereof, and a pharmaceutical composition including the compound, a method for preparing the pharmaceutical composition, and use of the compound or the pharmaceutical composition in the treatment or prevention of RORγt-mediated cancer, inflammation, or autoimmune diseases in mammals, especially humans.

公开(公告)号：US20230110165A1

公开(公告)日：2023-04-13

申请号：US17962273

申请日：2022-10-07

申请人： Proximagen, LLC

发明人： Max Espensen ,  Lee Patient ,  David Evans ,  Edward Savory ,  Iain Simpson

IPC分类号： C07D471/04 ,  A61K31/40 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/501 ,  A61K31/506 ,  C07C53/18

摘要： Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.

公开(公告)号：US20230087834A1

公开(公告)日：2023-03-23

申请号：US17932982

申请日：2022-09-16

申请人： THE GEORGE INSTITUTE FOR GLOBAL HEALTH

发明人： Anthony RODGERS ,  Stephen MacMAHON

IPC分类号： A61K31/4422 ,  A61P9/12 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/41 ,  A61K31/382 ,  A61K31/40 ,  A61K31/277 ,  A61K31/4178 ,  A61K31/517 ,  A61K31/4035 ,  A61K31/495 ,  A61K31/554 ,  A61K31/4418 ,  A61K31/549

摘要： Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

公开(公告)号：US11607412B2

公开(公告)日：2023-03-21

申请号：US17410897

申请日：2021-08-24

申请人： Tenax Therapeutics, Inc.

发明人： Stuart Rich ,  Douglas Randall ,  Douglas Hay

IPC分类号： A61K31/50 ,  A61K31/495 ,  A61K47/12 ,  A61K47/02 ,  A61K47/10 ,  A61K9/00 ,  A61K47/26 ,  A61K47/40 ,  A61K45/06 ,  A61K31/7048 ,  A61K31/55 ,  A61K31/502 ,  A61K38/22 ,  A61P9/12 ,  A61P9/04 ,  A61K31/41 ,  A61K31/216 ,  A61K47/32

摘要： This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

公开(公告)号：US11607410B2

公开(公告)日：2023-03-21

申请号：US16994425

申请日：2020-08-14

申请人： MannKind Corporation

发明人： Marshall L. Grant ,  Grayson W. Stowell ,  Paul Menkin ,  John J. Freeman, Jr.

IPC分类号： A61K31/495 ,  A61K9/00 ,  A61K9/14 ,  A61K38/28 ,  A61P5/00 ,  A61K38/00 ,  A61K9/16 ,  A61K9/19 ,  A61K45/06 ,  A61M15/00 ,  C07D241/08 ,  A61K31/5575 ,  A61K38/19

摘要： Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.

公开(公告)号：US20230078764A1

公开(公告)日：2023-03-16

申请号：US17441937

申请日：2020-03-20

申请人： Yumanity Therapeutics, Inc.

发明人： Bertrand LE BOURDONNEC ,  Matthew LUCAS ,  Kerem OZBOYA ,  Bhaumik PANDYA ,  Daniel TARDIFF ,  Parcharee TIVITMAHAISOON ,  Iwona WRONA

IPC分类号： A61K31/4439 ,  A61K31/495 ,  A61K31/17 ,  A61K31/436 ,  A61K31/475 ,  A61K31/166 ,  A61K39/395 ,  C07D401/12 ,  C07D495/04 ,  C07D417/12 ,  C07D405/14 ,  C07D413/12 ,  C07D401/14 ,  C07D213/75 ,  A61K31/501 ,  A61K31/506 ,  A61K31/444 ,  A61K31/497 ,  A61K31/519 ,  A61K31/44

摘要： The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

公开(公告)号：US11590125B2

公开(公告)日：2023-02-28

申请号：US17007902

申请日：2020-08-31

申请人： IRR, Inc.

发明人： Bruce Chandler May

IPC分类号： A61K31/495 ,  A61K31/47 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61K45/06

摘要： The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

公开(公告)号：US20230056846A1

公开(公告)日：2023-02-23

申请号：US17792557

申请日：2021-01-13

申请人： MEMORIAL SLOAN KETTERING CANCER CENTER

发明人： Luis Alberto Diaz ,  Benoit Rousseau ,  Neil H. Segal

IPC分类号： A61K31/495 ,  A61K33/243 ,  C07K16/28 ,  A61K9/00 ,  A61P35/00

摘要： In some embodiments the present invention provides methods useful for the treatment of MMR-proficient and/or microsatellite stable (MSS) cancers and also useful for enhancing the immunogenicity of MMR-proficient and/or microsatellite stable (MSS) cancer cells, enhancing the sensitivity of MMR-proficient and/or microsatellite stable (MSS) cancer cells to immune checkpoint blockade, inducing an MMR-deficient mutational signature in MMR-proficient and/or microsatellite stable (MSS) cancer cells, and/or increasing the frequency of both missense and InDel mutations in MMR-proficient and/or microsatellite stable (MSS) cancer cells. In some embodiments such methods involve administration of a combination of temozolomide and cisplatin, or a combination of temozolomide, cisplatin and an immune checkpoint inhibitor, to a subject in need thereof.

公开(公告)号：US20230053817A1

公开(公告)日：2023-02-23

申请号：US17791261

申请日：2021-01-08

申请人： The Brigham and Women's Hospital, Inc.

发明人： Fengfeng Bei ,  E. Antonio Chiocca

IPC分类号： C07K14/005 ,  A61P35/00 ,  A61P37/04 ,  A61P25/00 ,  A61K31/495 ,  A61K31/175 ,  C07K16/28 ,  A61K39/395

摘要： The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier (BBB), compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM). Further disclosed are a number of potential targeting peptide sequences identified that enhance permeation through the BBB, when inserted into the capsid of an adeno-associated virus (AAV).